By Ben Hirschler MADRID (Reuters) - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit. Some doctors had hoped that extending the use of Iressa in combination with chemotherapy would help to keep cancers at bay, even when tumor cells had started to develop resistance to the drug. ...
via Health News Headlines - Yahoo News http://ift.tt/YwypcE
No comments:
Post a Comment